Obesity and psoriasis: From the Medical Board of the National Psoriasis Foundation

Journal of the American Academy of Dermatology

Volumn 63, Issue 6, 2010, Pages 1058-1069

  Bremmer, Samuel ^a   Van Voorhees, Abby S ^b   Hsu, Sylvia ^c   Korman, Neil J ^d   Lebwohl, Mark G ^e   Young, Melodie ^f   Bebo Jr , Bruce F ^g   Blauvelt, Andrew ^a,h  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY   (United States)

^f Modern Dermatology Aesthetics Center   (United States)

^g National Psoriasis Foundation   (United States)

^h PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

BMI; Body mass index; HDL; High density lipoprotein; IFN ; IL; Interferon gamma; Interleukin; Odds ratio; OR; PASI; Psoriasis Area and Severity Index; TNF ; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; METHOXSALEN; TAZAROTENE; USTEKINUMAB;

ALCOHOL CONSUMPTION; BODY MASS; CLINICAL TRIAL; DEPRESSION; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; HYPERLIPIDEMIA; LIVER BIOPSY; LIVER FIBROSIS; NEPHROTOXICITY; NON PROFIT ORGANIZATION; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; REVIEW; RISK FACTOR; SOCIAL ISOLATION; WAR;

DERMATOLOGIC AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; OBESITY; PHOTOTHERAPY; PSORIASIS;

EID: 78650269980     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.09.053     Document Type: Review

References (89)

1. L. Mallbris, C.T. Ritchlin, and M. Stahle Metabolic disorders in patients with psoriasis and psoriatic arthritis Curr Rheumatol Res 8 2006 355 363
2. W. Sterry, B.E. Strober, and A. Menter Obesity in psoriasis: The metabolic, clinical and therapeutic implications. report of an interdisciplinary conference and review Br J Dermatol 157 2007 649 655
3. M. Wakkee, H.B. Thio, E.P. Prens, E.J. Sijbrands, and H.A. Neumann Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients Atherosclerosis 190 2007 1 9
4. G. Yosipovitch, A. DeVore, and A. Dawn Obesity and the skin: skin physiology and skin manifestations of obesity J Am Acad Dermatol 56 2007 901 916
5. B. Lindegard Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes Dermatologica 172 1986 298 304
6. T. Henseler, and E. Christophers Disease concomitance in psoriasis J Am Acad Dermatol 32 1995 982 986
7. L. Naldi, L. Chatenoud, D. Linder, A. Belloni Fortina, A. Peserico, and A.R. Virgili Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study J Invest Dermatol 125 2005 61 67
8. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
9. A.D. Cohen, M. Sherf, L. Vidavsky, D.A. Vardy, J. Shapiro, and J. Meyerovitch Association between psoriasis and the metabolic syndrome. A cross-sectional study Dermatology 216 2008 152 155
10. M.D. Herron, M. Hinckley, M.S. Hoffman, J. Papenfuss, C.B. Hansen, and K.P. Callis Impact of obesity and smoking on psoriasis presentation and management Arch Dermatol 141 2005 1527 1534
11. D.M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis Arch Dermatol Res 298 2006 321 328
12. Y.J. Chen, C.Y. Wu, J.L. Shen, S.Y. Chu, C.K. Chen, Y.T. Chang, and C.M. Chen Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome Arch Dermatol 144 2008 1571 1575
13. M.L. Murray, P.R. Bergstresser, B. Adams-Huet, and J.B. Cohen Relationship of psoriasis to obesity using same-gender siblings as controls for obesity Clin Exp Dermatol 34 2008 140 144
14. Prevalence of overweight and obesity among adults: United States, 1999-2002 Hyattsville (MD): National Center for Health Statistics 01/11/2007. Available from: http://www.cdc.gov/nchs/products/pubs/pubd/hestats/obese/obse99. htm. Accessed August 5, 2009.
15. S.P. Raychaudhuri, and E.M. Farber The prevalence of psoriasis in the world J Eur Acad Dermatol Venereol 15 2001 16 17
16. P.G. Shekelle, S.H. Woolf, M. Eccles, and J. Grimshaw Clinical guidelines: developing guidelines BMJ 318 1999 593 596
17. A.B. Gottlieb, R. Evans, S. Li, L.T. Dooley, C.A. Guzzo, and D. Baker Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial J Am Acad Dermatol 51 2004 534 542
18. K. Reich, F.O. Nestle, K. Papp, J.P. Ortonne, R. Evans, and C. Guzzo Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Lancet 366 2005 1367 1374
19. A. Menter, S.R. Feldman, G.D. Weinstein, K. Papp, R. Evans, and C. Guzzo A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis J Am Acad Dermatol 56 13 2007 31.e1-15. Epub 2006 Sep 6
20. K. Reich, A.B. Gottlieb, A. Kimball, and S. Li Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized clinical trials J Am Acad Dermatol 54 Suppl 1 2006 AB215
21. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115
22. K.A. Papp, R.G. Langley, M. Lebwohl, G.G. Krueger, P. Szapary, and N. Yeilding Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 371 2008 1675 1684
23. K. Gordon, N. Korman, E. Frankel, H. Wang, A. Jahreis, and R. Zitnik Efficacy of etanercept in an integrated multistudy database of patients with psoriasis J Am Acad Dermatol 54 2006 S101 S111
24. B. Strober, A. Gottlieb, C. Leonardi, and K. Papp Levels of response of psoriasis patients with different baseline characteristics treated with etanercept J Am Acad Dermatol 54 3, Suppl. 1 2006 AB220
25. A.B. Gottlieb, W.H. Boehncke, and M. Darif Safety and efficacy of alefacept in elderly patients and other special populations J Drugs Dermatol 4 2005 718 724
26. H. Gollnick, R. Bauer, C. Brindley, C.E. Orfanos, G. Plewig, H. Wokalek, and E. Hoting Acitretin versus etretinate in psoriasis: clinical and pharmacokinetic results of a German multicenter study J Am Acad Dermatol 19 1988 458 468
27. P.S. Yamauchi, D. Rizk, T. Kormeili, R. Patnaik, and N.J. Lowe G.D. Weinstein, Therapy of moderate to severe psoriasis 2003 Marcel Dekker New York 137 150
28. J.E. Brick, L.W. Moreland, F. Al-Kawas, W.W. Chang, R.D. Layne, and A.G. Di Bartolomeo Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients Semin Arthritis Rheum 19 1989 31 44
29. G. Langman, P.M. Hall, and G. Todd Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury J Gastroenterol Hepatol 16 2001 1395 1401
30. M. Newman, R. Auerbach, H. Feiner, R.S. Holzman, J. Shupack, and P. Migdal The role of liver biopsies in psoriatic patients receiving long-term methotrexate treatment. Improvement in liver abnormalities after cessation of treatment Arch Dermatol 125 1989 1218 1224
31. G. Weinstein, H. Roenigk, H. Maibach, J. Cosmides, K. Halprin, and M. Millard Psoriasis-liver-methotrexate interactions Arch Dermatol 108 1973 36 42
32. M.A. Berends, J. Snoek, E.M. de Jong, P.C. van de Kerkhof, M.G. van Oijen, and J.H. van Krieken Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent Aliment Pharmacol Ther 24 2006 805 811
33. H.H. Roenigk Jr., W.F. Bergfeld, R. St Jacques, F.J. Owens, and W.A. Hawk Hepatotoxicity of methotrexate in the treatment of psoriasis Arch Dermatol 103 1971 250 261
34. P. Rosenberg, H. Urwitz, A. Johannesson, A.M. Ros, J. Lindholm, and N. Kinnman Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment J Hepatol 46 2007 1111 1118
35. H. Zachariae Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 42 2000 531 534
36. N. Shibata, T. Hayakawa, N. Hoshino, T. Minouchi, A. Yamaji, and M. Uehara Effect of obesity on cyclosporine trough concentrations in psoriasis patients Am J Health Syst Pharm 55 1998 1598 1602
37. P. Gisondi, M. Del Gigio, V. Di Francesco, M. Zamboni, and G. Girolomoni Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial Am J Clin Nutr 88 2008 1242 1247
38. L. Mallbris, F. Granath, A. Hamsten, and M. Stahle Psoriasis is associated with lipid abnormalities at the onset of skin disease J Am Acad Dermatol 54 2006 614 621
39. S. Zamboni, G. Zanetti, G. Grosso, G.B. Ambrosio, S. Gozzetti, and A. Peserico Dietary behaviour in psoriatic patients Acta Derm Venereol Suppl (Stockh) 146 1989 182 183
40. R.D. Simons Additional studies on psoriasis in the tropics and in starvation camps J Invest Dermatol 12 1949 285 294
41. I. Rucevic, A. Perl, V. Barisic-Drusko, and M. Adam-Perl The role of the low energy diet in psoriasis vulgaris treatment Coll Antropol 27 Suppl. 1 2003 41 48
42. J.M. Porres Jejunoileal bypass and psoriasis Arch Dermatol 113 1977 983
43. J.E. de Menezes Ettinger, E. Azaro, C.A. de Souza, P.V. dos Santos Filho, C.A. Mello, and M. Neves Jr. Remission of psoriasis after open gastric bypass Obes Surg 16 2006 94 97
44. G. Higa-Sansone, S. Szomstein, F. Soto, O. Brasecsco, C. Cohen, and R.J. Rosenthal Psoriasis remission after laparoscopic roux-en-Y gastric bypass for morbid obesity Obes Surg 14 2004 1132 1134
45. A.R. Setty, G. Curhan, and H.K. Choi Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses Health Study II Arch Intern Med 167 2007 1670 1675
46. G.S. Hotamisligil, N.S. Shargill, and B.M. Spiegelman Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 1993 87 91
47. P.A. Kern, M. Saghizadeh, J.M. Ong, R.J. Bosch, R. Deem, and R.B. Simsolo The expression of tumor necrosis factor in human adipose tissue. regulation by obesity, weight loss, and relationship to lipoprotein lipase J Clin Invest 95 1995 2111 2119
48. G.S. Hotamisligil, P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance J Clin Invest 95 1995 2409 2415
49. P. Dandona, R. Weinstock, K. Thusu, E. Abdel-Rahman, A. Aljada, and T. Wadden Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss J Clin Endocrinol Metab 83 1998 2907 2910
50. H. Hauner, M. Bender, B. Haastert, and F. Hube Plasma concentrations of soluble TNF-alpha receptors in obese subjects Int J Obes Relat Metab Disord 22 1998 1239 1243
51. G.S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance Science 271 1996 665 668
52. G.S. Hotamisligil, and B.M. Spiegelman Tumor necrosis factor alpha: a key component of the obesity-diabetes link Diabetes 43 1994 1271 1278
53. C.H. Lang, C. Dobrescu, and G.J. Bagby Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output Endocrinology 130 1992 43 52
54. R.H. Eckel Insulin resistance: an adaptation for weight maintenance Lancet 340 1992 1452 1453
55. H. Dominguez, H. Storgaard, C. Rask-Madsen, T. Steffen Hermann, N. Ihlemann, and D. Baunbjerg Nielsen Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes J Vasc Res 42 2005 517 525
56. A. Johnston, S. Arnadottir, J.E. Gudjonsson, A. Aphale, A.A. Sigmarsdottir, and S.I. Gunnarsson Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation Br J Dermatol 159 2008 342 350
57. S. Kaur, K. Zilmer, C. Kairane, M. Kals, and M. Zilmer Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis Br J Dermatol 159 2008 1364 1367 Epub 2008 Jul 22
58. B. Vanizor Kural, A. Orem, G. Cimsit, Y.E. Yandi, and M. Calapoglu Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis Clin Chim Acta 328 2003 71 82
59. P. Rocha-Pereira, A. Santos-Silva, I. Rebelo, A. Figueiredo, A. Quintanilha, and F. Teixeira Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease Clin Chim Acta 303 2001 33 39
60. M. Seishima, M. Seishima, S. Mori, and A. Noma Serum lipid and apolipoprotein levels in patients with psoriasis Br J Dermatol 130 1994 738 742
61. L. Zheng, B. Nukuna, M.L. Brennan, M. Sun, M. Goormastic, and M. Settle Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease J Clin Invest 114 2004 529 541
62. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143-3421
63. P. Gisondi, G. Tessari, A. Conti, S. Piaserico, S. Schianchi, and A. Peserico Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study Br J Dermatol 157 2007 68 73
64. S. Boehncke, D. Thaci, H. Beschmann, R.J. Ludwig, H. Ackermann, and K. Badenhoop Psoriasis patients show signs of insulin resistance Br J Dermatol 157 2007 1249 1251
65. P. Ena, P. Madeddu, N. Glorioso, D. Cerimele, and A. Rappelli High prevalence of cardiovascular diseases and enhanced activity of the renin-angiotensin system in psoriatic patients Acta Cardiol 40 1985 199 205
66. A.A. Qureshi, H.K. Choi, A.R. Setty, and G.C. Curhan Psoriasis and the risk of diabetes and hypertension Arch Dermatol 145 2009 379 382
67. J. Shapiro, A.D. Cohen, M. David, E. Hodak, G. Chodik, and A. Viner The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study J Am Acad Dermatol 56 2007 629 634
68. M. Binazzi, P. Calandra, and P. Lisi Statistical association between psoriasis and diabetes: further results Arch Dermatol Res 254 1975 43 48
69. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
70. C. Reynoso-von Drateln, E. Martinez-Abundis, B.R. Balcazar-Munoz, R. Bustos-Saldana, and M. Gonzalez-Ortiz Lipid profile, insulin secretion, and insulin sensitivity in psoriasis J Am Acad Dermatol 48 2003 882 885
71. G.M. Lord, G. Matarese, J.K. Howard, R.J. Baker, S.R. Bloom, and R.I. Lechler Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression Nature 394 1998 897 901
72. T.G. Kirchgessner, K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes J Clin Invest 100 1997 2777 2782
73. C. Grunfeld, C. Zhao, J. Fuller, A. Pollack, A. Moser, and J. Friedman Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters J Clin Invest 97 1996 2152 2157
74. I.S. Farooqi, G. Matarese, G.M. Lord, J.M. Keogh, E. Lawrence, and C. Agwu Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency J Clin Invest 110 2002 1093 1103
75. C.L. McTernan, P.G. McTernan, A.L. Harte, P.L. Levick, A.H. Barnett, and S. Kumar Resistin, central obesity, and type 2 diabetes Lancet 359 2002 46 47
76. N. Ouchi, S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, and Y. Okamoto Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin Circulation 100 1999 2473 2476
77. W.S. Yang, W.J. Lee, T. Funahashi, S. Tanaka, Y. Matsuzawa, and C.L. Chao Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin J Clin Endocrinol Metab 86 2001 3815 3819
78. L. Naldi, A. Addis, S. Chimenti, A. Giannetti, M. Picardo, and C. Tomino Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis Dermatology 217 2008 365 373
79. L. Clark, and M. Lebwohl The effect of weight on the efficacy of biologic therapy in patients with psoriasis J Am Acad Dermatol 58 2008 443 446
80. E. Fitch, E. Harper, I. Skorcheva, S.E. Kurtz, and A. Blauvelt Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines Curr Rheumatol Rep 9 2007 461 467
81. V.E. Friedewald, J.C. Cather, J.M. Gelfand, K.B. Gordon, G.H. Gibbons, and S.M. Grundy AJC editor's consensus: psoriasis and coronary artery disease Am J Cardiol 102 2008 1631 1643
82. J.M. Gelfand, E.D. Dommasch, D.B. Shin, R.S. Azfar, S.K. Kurd, X. Wang, and A.B. Troxel The risk of stroke in patients with psoriasis J Invest Dermatol 129 2009 2327
83. S. Prodanovich, F. Ma, J.R. Taylor, C. Pezon, T. Fasihi, and R.S. Kirsner Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis J Am Acad Dermatol 52 2005 262 267
84. H.H. Roenigk Jr., R. Auerbach, H.I. Maibach, and G.D. Weinstein Methotrexate guidelines - revised J Am Acad Dermatol 6 1982 145 155
85. C.E. Griffiths, L. Dubertret, C.N. Ellis, A.Y. Finlay, A.F. Finzi, and V.C. Ho Ciclosporin in psoriasis clinical practice: an international consensus statement Br J Dermatol 150 Suppl 67 2004 11 23
86. P. Gisondi, C. Cotena, G. Tessari, and G. Girolomoni Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study J Eur Acad Dermatol Venereol 22 2008 341 344
87. R. Saraceno, C. Schipani, A. Mazzotta, M. Esposito, L. Di Renzo, A. De Lorenzo, and S. Chimenti Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis Pharmacol Res 57 2008 290 295
88. C. Irace, G. Mancuso, E. Fiaschi, A. Madia, G. Sesti, and A. Gnasso Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol Atherosclerosis 177 2004 113 118
89. M. Vis, M.T. Nurmohamed, G. Wolbink, A.E. Voskuyl, M.H.M.T. de Koning, and R.J. van de Stadt Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis J Rheumatol 32 2005 252 255